Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

COSCIENS Biopharma Inc T.AEZ


Primary Symbol: T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Bullboard Posts
Comment by slagheapon Jul 30, 2015 3:39am
111 Views
Post# 23974732

RE:RE:Why is this company trading at $0.19?

RE:RE:Why is this company trading at $0.19?The company has entered into a large dilution financing with vulture funds who short the stock daily on big volume and probably profit a penny a share daily on their 3m to 6m shares traded per day. every day. It is poisonous for retail investors as seekingalpha warned. Have you noticed those three or four analysts with buy ratings on the stock and price targets of $1.50. They would be part of the group fleecing retail investors. Management is right in the middle of it. CEO Mr Dodd is 65 years old and making $586k per year according to Yahoo and he will be gone within a year or two. That`s how poisonous this company has become.
Bullboard Posts